Third generation fibric acid derivative. Elderly patients and those with im- paired renal function should not receive more than 67 mg per day.
Fenofibrate use requires periodic monitoring of serum lipids.
Therapy should not be continued if improvement in lipid profile is not seen after two months of therapy. Due to the potential for mild to moderate decreases in hemoglobin, hematocrit and WBC count, periodic hematologic monitoring should be conducted during the first 12 months of therapy. Long term monitoring is usually not required, as levels tend to stabilize with continued treatment. Fenofibrate therapy has been associated with elevated liver function tests and cholelithiasis. Discontinue therapy if liver function tests are elevated above three times the upper limit of normal.